Effects of weight loss and pharmacotherapy on inflammatory markers of cardiovascular disease

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 4, 2005, Pages 743-759

  Miller, Wendy M ^a   Nori Janosz, Katherine E ^a   Yanez, Jose ^a   McCullough, Peter A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Angiotensin II Type I receptor blockers; Angiotensin converting enzyme inhibitors; Aspirin; Cardiovascular disease; Inflammation; Metabolic syndrome; Metformin; Obesity; Statins; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ACYLATION STIMULATING PROTEIN; ADIPONECTIN; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOBESITY AGENT; ATORVASTATIN; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; METFORMIN; NICOTINIC ACID; PHENTERMINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; RESISTIN; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETES MELLITUS; EPIDEMIC; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LOW FAT DIET; OBESITY; PREVALENCE; REVIEW; THROMBOSIS; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; OBESITY; WEIGHT LOSS;

EID: 23144435943     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.3.4.743     Document Type: Review

References (141)

1. Libby P. Inflammation in atherogenesis. Nature 420, 868-874 (2003).
2. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes. Res. 12, 180-186 (2004).
3. Pittas AG, Joseph NA. Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metabol. 89, 447-452 (2004).
4. Wisse BE. The inflammatory syndrome: The role of adipose tissue cytokines in metabolic disorders linked to obesity. J. Am. Soc. Nephrol. 15(11), 2792-2800 (2004).
5. Engeli S, Schling P, Gorzelniak K et al. The adipose-tissue rennin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell. Biol. 35, 807-825 (2003).
6. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metabol. 89(6), 2601-2607 (2004).
7. Ziccardi P, Nappo F, Giugliano G et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105, 804-809 (2002).
8. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr. Med. Chem. Cardiovasc. Hematol. Agents 2(3), 197-208 (2004).
9. Einhorn D, Aroda VR, Henry R. Glitazones and the management of insulin resistance: what they do and how might they be used. Endocrinol. Metab. Clin. N. Am. 33, 595-616 (2004).
10. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
11. Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 35, 982-984 (1992).
12. Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J. Clin. Endocrinol. Metabol. 82, 4196-4200 (1997).
13. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metabol. 83, 847-850 (1998).
14. Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metabol. 85, 3338-3342 (2000).
15. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621-636 (1990).
16. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 11, 1805-1812 (2003).
17. Burstein SA, Peng J, Friese P et al. Cytokine-induced alteration of platelet and hemostatic function. Stem Cells 14(Suppl.1), 154-162 (1996).
18. Wassman S, Stumpf M, Strehlow K et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II Type 1 receptor. Circ. Res. 94, 534-541 (2004).
19. Carr MC, Brunzell JD. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of Type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J. Clin. Endocrinol. Metabol. 89(6), 2601-2607 (2004).
20. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature 404, 661-671 (2000).
21. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337-350 (2004).
22. Gainsford T, Willson TA, Metcalf D et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc. Natl Acad. Sci. USA 93, 14564-14568 (1996).
23. Raso GM, Pacilio M, Esposito E, Coppola A, Di Carlo R, Meli R. Leptin potentiates IFN-γ-induced expression of nitric oxide synthase and cyclo-oxygenase-2 in murine macrophage J774A. 1. Br. J. Pharmacol. 187, 799-804 (2002).
24. Bornstein SR, Licinio J, Tauchnitz R et al. Plasma leptin levels are increased in survivors of acute sepsis: Associated loss of diurnal rhythm, in cortisol and leptin secretion. J. Clin. Endocrinol. Metabol. 83, 280-283 (1998).
25. Hasty AH, Shimano H, Osuga J et al. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem. 276, 37402-37408 (2001).
26. Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104, 3052-3056 (2001).
27. Shamsuzzaman ASM, Winnicki M, Volk R et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109, 2181-2185 (2004).
28. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95, 2409-2415 (1995).
29. Tsigos C, Kyrou I, Chala E et al. Circulating tumor necrosis factor-α concentrations are higher in abdominal versus peripheral obesity. Metabolism 48, 1332-1335 (1999).
30. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: Relation to obesity, insulin resistance, and tumor necrosis factor-α expression. Diabetes 52, 1779-1785 (2003).
31. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev. 14, 447-455 (2003).
32. Samad F, Teoman K, Wiesbrock SM et al. Tumor necrosis factor α is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc. Natl Acad. Sci. USA 96, 6902-6907 (1999).
33. Yudkin JS, Stehouwer CDA, Emeis JJ et al. C-reactive protein in healthy subjects: associations with obesity insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue. Arterioscler. Thromb. Vasc. Biol. 19, 972-978 (1999).
34. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. Relat. Metab. Disord. 28(11), 1357-1364 (2004).
35. Halleux CM, Declerck PJ, Tran SL, Detry R, Brichard SM. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J. Clin. Endocrinol. Metabol. 84, 4097-4105 (1999).
36. Takahashi D, Tamura K, Ushikubo T et al. Relationship between hepatic angiotensinogen mRNA expression and plasma angiotensinogen in patients with chronic hepatitis. Life Sci. 60, 1623-1633 (1997).
37. Schorr U, Blaschke K, Turan S et al. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J. Hypertens. 16, 1475-1480 (1998).
38. Tamura K, Umemura S, Yamakawa T et al. Modulation of tissue angiotensinogen gene expression in genetically obese hypertensive rats. Am. J. Physiol. 272, R1704-1711 (1997).
39. Van Harmelen V, Ariapart P, Hoffstedt J et al. Increased adipose angiotensinogen gene expression in human obesity. Obes. Res. 8(4) 337-341 (2000).
40. Schieffer B, Drexler H. Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular disease. Am. J. Cardiol. 91(Suppl.), 12H-18H (2003).
41. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotenin IV. J. Clin. Invest. 96, 2515-2520 (1995).
42. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induces JAK/STAT signaling and cytokine induction. Circ. Res. 87, 1195-1201 (2000).
43. Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W, Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1623-1629 (1999).
44. Goldstein BJ, Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J. Clin. Endocrinol. Metabol. 89(6), 2563-2568 (2004).
45. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 26, 2442-2450 (2003).
46. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation 100, 2473-2476 (1999).
47. Hotta K, Funahashi T. Arita Y et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in Type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20, 1595-1599 (2000).
48. Tan KC, Xu A, Chow WS. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J. Clin. Endocrinol. Metabol. 89, 765-769 (2004).
49. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42, 231-234 (2003).
50. Shimabukuro M, Higa N, Asahi T. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J. Clin. Endocrinol. Metabol. 88, 3236-3240 (2003).
51. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 278, 45021-45026 (2003).
52. Brakenhielm E, Veitonmaki N, Cao R et al. Adiponectin-induced anti-angiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl Acad. Sci. USA 101, 2476-2481 (2004).
53. Rajala MW, Scherer PE. Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765-3773 (2003).
54. Sniderman AD, Maslowska M, Cianflone K. Of mice and men (and women) and the acylation-stimulating protein pathway. Curr. Opin. Lipidol. 11, 291-296 (2000).
55. Cottam DR, Mattar SG, Barinas-Mitchell E et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes. Surg. 14, 589-600 (2004).
56. Garg A. Dyslipoproteinemia and diabetes. Endocrinol. Metab. Clin. N. Am. 27(3), 613-626 (1998).
57. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides and low HDL-C cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 36, 226-232 (2000).
58. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94, 1172-1179 (1994).
59. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43, 104-109 (1994).
60. Einhorn D, Reaven GM, Cobin RH et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9(3), 237-252 (2003).
61. Lemieux I, Pascot A, Prud'homme D et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler. Thromb. Vasc. Biol. 21, 961-967 (2001).
62. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000).
63. Ridker PM, Morrow DA. C-reactive protein, inflammation, and coronary risk. Cardiol. Clin. 21, 315-325 (2003).
64. Van der Meer IM, de Maat MPM, Hak AE et al. C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree. The Rotterdam Study. Stroke 33, 2750-2755 (2002).
65. Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321, 199-204 (2000).
66. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004).
67. Roberts WL, Moulton L, Law TC et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 47, 418-425 (2001).
68. Pearson TA, Mensah GA, Alexander RW et al. AHA/CDC Scientific Statement: markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511 (2003).
69. Burke AP, Tracy RP, Kolodgie F et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 105, 2019-2023 (2002).
70. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102, 2165-2168 (2000).
71. Pasceri V, Cheng JS, Willerson JT et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531-2534 (2001).
72. Verma S, Li SH, Badiwala MV et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105, 1890-1896 (2002).
73. Nakagomi A, Freedman SB, Geczy CL. Interferon-γ and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 101, 1785-1791 (2000).
74. Mousa SA, Bozarth JM. Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin. J. Am. Coll. Cardiol. 38, 202A (2002).
75. Devarai S, Xu DY, Jiala I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404 (2003).
76. Venuogopal SK, Devarai S, Yuhanna I et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 106, 1439-1441 (2002).
77. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913-919 (2002).
78. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352(1), 73-75 (2005).
79. Torgerson JS, Carlsson B, Stenlof K, Carlsson LM, Bringman E, Sjostrom L. A low serum leptin level at baseline and a large early decline in leptin predict a large 1-year weight reduction in energy-restricted obese humans. J. Clin. Endocrinol. Metabol. 84(11), 4197-4204 (1999).
80. Brook RD, Bard RL, Glazewski L et al. Effect of a short-term weight loss on the metabolic syndrome and conduit vascular endothelial function in overweight adults. Am. J. Cardiol. 83, 1012-1016 (2004).
81. Liu YM, Lacorte JM, Viguerie N et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J. Clin. Endocrin. Metabol. 88(12), 5881-5886 (2003).
82. Xydakis AM, Case CC, Jones PH et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metabol. 89(6), 2697-2703 (2004).
83. Seshadri P, Iqbal N, Stern L et al. A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am. J. Med. 117, 398-405 (2004).
84. ATP III Final Report. II. Rationale for intervention. Circulation 106, 3163-3223 (2002).
85. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler. Thromb. Vasc. Biol. 21, 968-970 (2001).
86. Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. 101(17), 6659-6663 (2004).
87. Nicklas BJ, Ambrosius W, Messier SP et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am. J. Clin. Nutr. 79, 544-551 (2004).
88. You T, Berman DM, Ryan AS, Nicklas BJ et al. Effects of hypocaloric diet and exercise training on inflammation and adipocyte lipolysis in obese postmenopausal women. J. Clin. Endocrinol. Metabol. 89, 1739-1746 (2004).
89. Kasapis C, Thompson PD. The effects of physical activity on serum C-reactive protein and inflammatory markers. J. Am. Coll. Cardiol. 45, 1563-1569 (2005).
90. Van Dielen FMH, Buurman WA, Hadfoune M, Nijhuis J, Greve JW. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J. Clin. Endocrinol. Metabol. 89, 4062-4068 (2004).
91. Vásquez LA, Pazos F, Berrazueta JR et al. Effects of changes in body weight and insulin resistance on inflammation and endothelial function in morbid obesity after bariatric surgery. J. Clin. Endocrinol. Metabol. 90, 316-322 (2005).
92. Sharman MJ, Volek JS. Weight loss leads to reductions in inflammatory biomarkers after a very-low-carbohydrate diet and a low-fat diet in overweight men. Clin. Sci. (Lond.) 107(4), 365-369 (2004).
93. Bastard JP, Jardel C, Bruckert E et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metabol. 85, 3338-3342 (2000).
94. Jarvi AE, Karlstrom BE, Granfeldt YE et al. Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in Type 2 diabetic patients. Diabetes Care 22, 10-18 (1999).
95. Colwell JA. Treatment for the procoagulant state in Type 2 diabetes. Endocrinol. Metab. Clin. N. Am. 30(4), 1011-1030 (2001).
96. Harp JB, Henry SA, DiGirolamo M. Dietary weight loss decreases serum angiotensin-converting enzyme activity in obese adults. Obes. Res. 10(10), 985-990 (2002).
97. Tsai AG, Wadden T. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann. Intern. Med. 142, 56-66 (2005).
98. Hannum SM, Carson L, Evans EM et al. Use of portion-controlled entrees enhances weight loss in women. Obes. Res. 12, 538-546 (2004).
99. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292(14), 1724-1737 (2004).
100. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
101. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. 27, 1437-1446 (2003).
102. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: Therapeutic targets. J. Clin. Endocrinol. Metabol. 89(6), 2616-2621 (2004).
103. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973-979 (1997).
104. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100, 793-798 (1999).
105. Feldman M, Jialal I, Devaraj D, Cryer B. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J. Am. Coll. Cardiol. 37, 2036-2041 (2001).
106. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169(1), 155-158 (2003).
107. Chew DP, Bhatt DL, Robbins MA et al. Effects of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am. J. Cardiol. 88, 672-674 (2001).
108. Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 23(9), 1141-1152 (2003).
109. Kranzhöfer R, Schmidt J, Pfeiffer CAH, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 19, 1623-1629 (1999).
110. Bünte C, Witte J, Hoeper K, Schieffer B. Contrasting anti-atherosclerotic effects of AT1-antagonism and ACE inhibition in patients with coronary artery disease: potential impact on plaque passivation. Circulation 19, II-337 (2002) (Abstract 1684).
111. Takeda T, Hoshida S, Nishino M, Tanouchi J, Otsu K, Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 169(1), 155-158 (2003).
112. Andersen S, Schalkwijk CG, Stehouwer CDA, Parving HH. Angiotensin II blockade is associated with decreased plasma leukocyte adhesion molecule levels in diabetic nephropathy [letter]. Diabetes Care 23, 1032-1032 (2000).
113. Ridker PM, Rifai N, Pfeffer MA et al. for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 98, 839-844 (1998).
114. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E; for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 100, 230-235 (1999).
115. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286, 64-70 (2001).
116. Costa A, Casamitjana R, Casals E et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet. Med. 20, 743-745 (2003).
117. Kinlay S, Timms T, Clark M et al. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischaemia. Am. J. Cardiol. (89) 1205-1207 (2002).
118. Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am. J. Cardiol. 91, 14B-22B (2003).
119. Maison P, Mennen L, Sapinho et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 160, 155-160 (2002).
120. Balk EM, Lau J, Goudas LC et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 139, 670-682 (2003).
121. Jonkers IJ, Mohrschladt MF, Westendorp RG, can der Laarse A, Smelt AH. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am. J. Med. 112(4), 275-280 (2002).
122. Stein JH, Rosenson RS. Treatment of severe hypertriglyceridemia lowers plasma viscosity. Atherosclerosis 137, 401-405 (1998).
123. Malik J, Melenovsky V, Wichterle D et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc. Res. 52, 290-298 (2001).
124. Chesney CM, Herd JA, Elam MB et al. Niacin lowers fibrinogen in patients with peripheral artery disease (PAD). Circulation 94, S84 (1996) (Abstract).
125. De Jager J, Kooy A, Lehert P et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in Type 2 diabetes mellitus: a randomized, placebo-controlled trial. Intern. Med. 257(1), 100-109 (2005).
126. Biarnés J, Fernández-Real JM, Fernández-Castaner M, del Mar García M, Soler J, Ricart W. Differential regulation of insulin action and tumor necrosis factor a system activity by metformin. Metab. Clin. Exp. 54, 235-239 (2005).
127. Caballero AE, Delgado A, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. Clin. Endocrinol. Metabol. 89(8), 3943-3948 (2004).
128. Haffner SM, Greenberg, Weston WM, Chen H, Williams K, Freed MI. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 106, 679-684 (2002).
129. Wang TD, Chen WJ, Jin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome. Am. J. Cardiol. 93(3), 362-365 (2004).
130. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in Type 2 diabetes. Am. J. Cardiol. 90, 947-952 (2002).
131. Satoh N, Ogawa Y, Usui T et al. Anti-atherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26(9), 2493-2499 (2003).
132. Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 25, 542-549 (2002).
133. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR. Metabolic syndrome: Evaluation of pathological and therapeutic outcomes. Am. Heart J. 149(1), 20-32 (2004).
134. Koshiyama H, Shimono D, Kuwamura N et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J. Clin. Endocrinol. Metabol. 86, 3452-3456 (2001).
135. NCEP Expert Panel. Third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421 (2002).
136. Lara-Castro C, Garvey WT. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J. Clin. Endocrinol. Metabol. 89(9), 4197-4205 (2004).
137. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304 (2005).
138. Grundy SM, Sleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227-239 (2004).
139. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from Type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J. Clin. Endocrinol. Metabol. 89(11) 5535-5541 (2004).
140. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta cell function of subjects with Type 2 diabetes. Diabetes Care 11, 2589-2589 (2004).
141. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet 352, 854-856 (1998).